Importer of Controlled Substances Application: Myoderm, 71474 [2019-27954]
Download as PDF
<![CDATA[
71474
Federal Register / Vol. 84, No. 248 / Friday, December 27, 2019 / Notices
The company plans to import the
listed controlled substances to
manufacture bulk active pharmaceutical
ingredients (API) for distribution to its
customers.
Dated: December 10, 2019.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2019–27953 Filed 12–26–19; 8:45 am]
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
ADDRESSES:
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–552]
Importer of Controlled Substances
Application: Myoderm
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 27, 2020. Such
persons may also file a written request
for a hearing on the application on or
before January 27, 2020.
DATES:
Notice of application.
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on October 14, 2019,
Myoderm, 48 East Main Street,
Norristown, Pennsylvania 19401–4915
applied to be registered as an importer
of the following basic classes of
controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Amphetamine ...........................................................................................................................................................
Lisdexamfetamine ....................................................................................................................................................
Methylphenidate .......................................................................................................................................................
Nabilone ...................................................................................................................................................................
Oxycodone ...............................................................................................................................................................
Hydromorphone .......................................................................................................................................................
Hydrocodone ............................................................................................................................................................
Morphine ..................................................................................................................................................................
Oxymorphone ..........................................................................................................................................................
Fentanyl ...................................................................................................................................................................
The company plans to import the
listed controlled substances for clinical
trials, research, and analytical purposes.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of FDA approved or nonapproved finished dosage forms for
commercial sale.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
[FR Doc. 2019–27952 Filed 12–26–19; 8:45 am]
ADDRESSES:
Drug Enforcement Administration
Controlled substance
BILLING CODE 4410–09–P
[Docket No. DEA–566]
jbell on DSKJLSW7X2PROD with NOTICES
Dated: December 10, 2019.
William T. McDermott,
Assistant Administrator.
DEPARTMENT OF JUSTICE
[FR Doc. 2019–27954 Filed 12–26–19; 8:45 am]
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
DATES:
VerDate Sep<11>2014
18:44 Dec 26, 2019
Jkt 250001
SUPPLEMENTARY INFORMATION:
Methylphenidate .......
Hydromorphone ........
Hydrocodone ............
Oripavine ..................
Thebaine ...................
Tapentadol ................
Bulk Manufacturer of Controlled
Substances Application: Janssen
Pharmaceuticals Inc.
1100
1205
1724
7379
9143
9150
9193
9300
9652
9801
comments on or objections to the
issuance of the proposed registration on
or before February 25, 2020.
In
accordance with 21 CFR 1301.33(a), this
is notice that on October 9, 2019,
Janssen Pharmaceuticals Inc., Buildings
1–5 & 7–14, 1440 Olympic Drive,
Athens, Georgia 30601 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
Dated: November 13, 2019.
William T. McDermott,
Acting Assistant Administrator.
Schedule
Drug
code
1724
9150
9193
9330
9333
9780
Frm 00127
Fmt 4703
Sfmt 4703
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Notice To Ensure State Workforce
Agencies Are Aware of the Revised
Schedule of Remuneration for the
Unemployment Compensation for ExService Members (UCX) Program That
Reflects the Military Pay Increase
Effective January 1, 2020
Employment and Training
Administration, Labor.
ACTION: Notice.
AGENCY:
Schedule
II
II
II
II
II
II
The company plans to manufacture
the above-listed controlled substances
in bulk for distribution to its customers.
PO 00000
II
II
II
II
II
II
II
II
II
II
Each year, the Department of
Defense issues a Schedule of
Remuneration used by states for UCX
purposes. States must use the schedule
to determine Federal military wages for
UCX ‘‘first claims’’ only when the
Federal Claims Control Center (FCCC)
responds to a request for information
indicating that there is no Copy 5 of the
SUMMARY:
E:\FR\FM\27DEN1.SGM
27DEN1
]]>Agencies
[Federal Register Volume 84, Number 248 (Friday, December 27, 2019)]
[Notices]
[Page 71474]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-27954]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-552]
Importer of Controlled Substances Application: Myoderm
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before January 27, 2020.
Such persons may also file a written request for a hearing on the
application on or before January 27, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on October 14, 2019, Myoderm, 48 East Main Street,
Norristown, Pennsylvania 19401-4915 applied to be registered as an
importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Amphetamine............................. 1100 II
Lisdexamfetamine........................ 1205 II
Methylphenidate......................... 1724 II
Nabilone................................ 7379 II
Oxycodone............................... 9143 II
Hydromorphone........................... 9150 II
Hydrocodone............................. 9193 II
Morphine................................ 9300 II
Oxymorphone............................. 9652 II
Fentanyl................................ 9801 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
clinical trials, research, and analytical purposes. Approval of permit
applications will occur only when the registrant's business activity is
consistent with what is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the import of FDA approved or non-
approved finished dosage forms for commercial sale.
Dated: November 13, 2019.
William T. McDermott,
Acting Assistant Administrator.
[FR Doc. 2019-27954 Filed 12-26-19; 8:45 am]
BILLING CODE 4410-09-P
